Source - RNS
RNS Number : 6613K
OptiBiotix Health PLC
23 September 2016
 

OptiBiotix Health plc

 

("OptiBiotix" or the "Company")

 

Exercise of Warrants and Issue of Equity

 

OptiBiotix Health plc (AIM: OPTI), a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes announces that the Company has received notification from warrant holders to exercise warrants over 34,050 ordinary shares of 2p each in the Company at an exercise price of 8p per share, providing the Company with gross proceeds of £2,724.

 

Application will be made to the London Stock Exchange to admit the 34,050 new ordinary shares to trading on AIM.  Admission of the new ordinary shares is expected to occur on or around 28 September 2016.  The new ordinary shares will rank pari passu with the existing ordinary shares.

 

For the purpose of the Disclosure and Transparency Rules, following the issue of shares detailed above the enlarged issued share capital of the Company will comprise 78,150,534 ordinary shares of 2p each. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information:

OptiBiotix Health plc

www.optibiotix.com

Stephen O'Hara, Chief Executive

Contact via Walbrook below



Cairn Financial Advisers LLP

Tel: 020 7148 7900

Liam Murray / Tony Rawlinson




Hybridan LLP (Joint Broker)

Claire Louise Noyce

 

 

Tel: 020 3764 2341

Peterhouse Corporate Finance Ltd (Joint Broker)

Tel: 020 7469 0936

Lucy Williams / Duncan Vasey




Walbrook PR Ltd

Tel: 020 7933 8780 or [email protected]

Anna Dunphy

Mob: 07876 741 001

Mike Wort

Mob: 07900 608 002

 

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease. 

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCZMGZLNFKGVZG

Related Charts

Optibiotix Health (OPTI)

0.00 (0.00%)
delayed 18:15PM